Readmissions for Heart Failure in Children

Area of Science:

• Pediatric Cardiology
• Cardiovascular Research
• Pharmacotherapy Efficacy

Background:

• Pediatric heart failure (HF) and cardiomyopathy (CMP) are serious conditions requiring intensive management.
• Readmissions after initial hospitalization pose a significant burden on patients, families, and healthcare systems.
• Understanding readmission drivers is crucial for improving care transitions in pediatric HF.

Purpose of the Study:

• To determine the frequency of 30-day hospital readmissions for heart failure in children diagnosed with cardiomyopathy.
• To evaluate the impact of discharge pharmacotherapy on the rate of 30-day readmissions for heart failure in this pediatric population.

Main Methods:

• Utilized the Pediatric Health Information System Database (2004-2013) for patients aged 18 years or younger with HF or CMP codes.
• Excluded patients with congenital heart disease, in-hospital mortality, or prior cardiac surgery.
• Employed mixed-effects multivariable logistic regression to identify factors associated with 30-day readmission.

Main Results:

• A total of 2386 pediatric patients met the inclusion criteria.
• The 30-day readmission rate for heart failure was 12.9%.
• Discharge use of milrinone or beta-blockers, and higher institutional HF patient volume were linked to increased readmission odds; mechanical ventilation during initial admission was associated with decreased odds.

Conclusions:

• Pediatric patients with cardiomyopathy and heart failure exhibit a high incidence of 30-day heart failure-related readmissions.
• Current outpatient pharmacotherapy regimens at discharge do not appear to significantly influence readmission rates.
• Further investigation is warranted to identify effective strategies for reducing readmissions in this vulnerable pediatric population.